In vitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 – Results from the SMART global surveillance program

Diagnostic Microbiology and Infectious Disease

Volumn 88, Issue 2, 2017, Pages 171-176

  Lob, Sibylle H ^a   Hackel, Meredith A ^a   Kazmierczak, Krystyna M ^a   Hoban, Daryl J ^a,b   Young, Katherine ^c   Motyl, Mary R ^c   Karlowsky, James A ^b   Sahm, Daniel F ^a  

^a Division of Microbiology   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Imipenem; Relebactam; Respiratory; SMART; Surveillance

Indexed keywords

IMIPENEM; RELEBACTAM; ANTIINFECTIVE AGENT; AZABICYCLO DERIVATIVE; BETA LACTAMASE INHIBITOR; MK-7655;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; ENTEROBACTERIACEAE; IN VITRO STUDY; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; NON PROTEEAE ENTEROBACTERIACEAE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; UNITED STATES; COMBINATION DRUG THERAPY; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASE INHIBITORS; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; IMIPENEM; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, VENTILATOR-ASSOCIATED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; UNITED STATES;

EID: 85014776176     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2017.02.018     Document Type: Article

References (28)

1. Agrafiotis, M., Siempos, I.I., Ntaidou, T.K., Falagas, M.E., Attributable mortality of ventilator-associated pneumonia: a meta-analysis. Int J Tuberc Lung Dis 15 (2011), 1154–1163.
2. Bassetti, M., De Waele, J.J., Eggimann, P., Garnacho-Montero, J., Kahlmeter, G., Menichetti, F., et al. Preventative and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 41 (2015), 776–795.
3. Blizzard, T.A., Chen, H., Kim, S., Wu, J., Bodner, R., Gude, C., et al. Discovery of MK-7655, β-lactamase inhibitor for combination with Primaxin®. Bioorg Med Chem Lett 24:3 (2014), 780–785.
4. Boucher, H.W., Talbot, G.H., Bradley, J.S., Edwards, J.E. Jr., Gilbert, D., Rice, L.B., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009), 1–12.
5. Centers for Disease Control and Prevention (CDC), Antibiotic resistance threats in the United States. Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/arthreats-2013-508.pdf, 2013.
6. Centers for Disease Control and Prevention (CDC), Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 62 (2013), 165–170.
7. Clinical and Laboratory Standards Institute (CLSI), Performance standards for antimicrobial susceptibility testing. Twenty-sixth informational supplement M100-S26. 2016, CLSI, Wayne, PA, USA.
8. Clinical and Laboratory Standards Institute (CLSI), Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: tenth edition: approved standard M07-A10. 2015, CLSI, Wayne, PA, USA [ClinicalTrials.gov. https://clinicaltrials.gov/ct2/results?term=MK-7655&Search=Search].
9. Daikos, G.L., Tsaousi, S., Tzouvelekis, L.S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections; lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58 (2014), 2322–2328.
10. Drawz, S.M., Papp-Wallace, K.M., Bonomo, R.A., New β-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 58 (2014), 1835–1846.
11. European Committee on Antimicrobial Susceptibility Testing, Breakpoint tables for interpretation of MICs and zone diameters, version 6.0 (valid from 2016–01-01). http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_6.0_Breakpoint_table.pdf, 2016.
12. Kalil, A.C., Metersky, M.L., Klompas, M., Muscedere, J., Sweeney, D.A., Palmer, L.B., et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis, 2016, 10.1093/cid/ciw353.
13. Kanj, S.S., Kanafani, Z.A., Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86 (2011), 250–259.
14. Kaye, K.S., Pogue, J.M., Infections caused by resistant gram-negative bacteria: epidemiology and management. Pharmacotherapy 35 (2015), 949–962.
15. KPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime-avibactam and aztreonam-avibactam. Antimicrob Agents Chemother 60 (2016), 4490–4500.
16. Kumar, A., Roberts, D., Wood, K.E., Light, B., Parrillo, J.E., Sharma, S., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 (2006), 1589–1596.
17. Kollef, M.H., Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 31:Suppl. 4 (2000), S131–S138.
18. Lapuebla, A., Abdallah, M., Olafisoye, O., Cortes, C., Urban, C., Landman, D., et al. Activity of imipenem with relebactam against gram-negative pathogens from New York City. Antimicrob Agents Chemother 59 (2015), 5029–5031.
19. Livermore, D.M., Interplay of impermeability and chromosomal β-lactamase activity in imipenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother, 1992, 2046–2048.
20. Livermore, D.M., Warner, M., Mushtaq, S., Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 68 (2013), 2286–2290.
21. Lob, S.H., Hoban, D.J., Sahm, D.F., Badal, R.E., Regional differences and trends in antimicrobial susceptibility of Acinetobacter baumannii. Int J Antimicrob Agents 47 (2016), 317–323.
22. Lob, S.H., Kazmierczak, K.M., Badal, R.E., Hackel, M.A., Bouchillon, S.K., Biedenbach, D.J., et al. Trends in susceptibility of Escherichia coli from intra-abdominal infections to ertapenem and comparators in the United States according to data from the SMART program, 2009 to 2013. Antimicrob Agents Chemother 59 (2015), 3606–3610.
23. Magill, S.S., Edwards, J.R., Fridkin, S.K., Emerging infections program healthcare-associated infections antimicrobial use survey team. Survey of healthcare-associated infections. N Engl J Med 370 (2014), 2542–2543.
24. Nichols, W.W., de Jonge, B.L., Kazmierczak, K.M., Karlowsky, J.A., Sahm, D.F., In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 60 (2016), 4743–4749.
25. Olsen, I., New promising β-lactamase inhibitors for clinical use. Eur J Clin Microbiol Infect Dis 34 (2015), 1303–1308.
26. Pogue, J.M., Kaye, K.S., Cohen, D.A., Marchaim, D., Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clin Microbiol Infect 21 (2015), 302–312.
27. Young, K., Raghoobar, S.L., Hairston, N.N., Painter, R.E., Racine, F., Dorso, K.L., et al. In vitro activity of the class A and C β-lactamase inhibitor MK-7655. Poster F1–2139 ICAAC, 2010 [Boston, MA].
28. Winkler, M., Hujer, A.M., Bethel, C.R., Domitrovic, T.N., Young, K., Bonomo, R.A., Imipenem-cilastatin-relebactam (IMI/REL): an analysis of resistance in Pseudomonas aeruginosa (Pa) isolates. Poster C-147 ICAAC/ICC, 2015 [San Diego, CA].